Influence of pH conditions on the viability of Saccharomyces boulardii yeast

Journal of General and Applied Microbiology

Volumn 54, Issue 4, 2008, Pages 221-227

  Graff, Sandrine ^a   Chaumeil, Jean Claude ^a   Boy, Pierre ^b   Lai Kuen, René ^a   Charrueau, Christine ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acidic conditions; Saccharomyces boulardii; Viability

Indexed keywords

PROBIOTIC AGENT;

AQUEOUS SOLUTION; ARTICLE; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BIOAVAILABILITY; FREEZE DRYING; IN VITRO STUDY; INTESTINE FLORA; MICROBIAL VIABILITY; NONHUMAN; SACCHAROMYCES BOULARDII; SCANNING TRANSMISSION ELECTRON MICROSCOPY; SENSITIVITY ANALYSIS; SOLVENT EFFECT; STOMACH PH; STOMACH PROTECTION; BACTERIAL COUNT; BIOLOGICAL MODEL; COLON; CYTOLOGY; GASTROINTESTINAL TRANSIT; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIOLOGY; PH; SACCHAROMYCES; SCANNING ELECTRON MICROSCOPY; STOMACH;

SACCHAROMYCES BOULARDII;

COLON; COLONY COUNT, MICROBIAL; FREEZE DRYING; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, SCANNING; MODELS, BIOLOGICAL; PROBIOTICS; SACCHAROMYCES; STOMACH;

EID: 52649145404     PISSN: 00221260     EISSN: 13498037     Source Type: Journal    
DOI: 10.2323/jgam.54.221     Document Type: Article

References (23)

1. Bai, F. W., Chen, L. J., Zhang, Z., Anderson, W. A., and Moo-Young, M. (2004) Continuous ethanol production and evaluation of yeast cell lysis and viability loss under very high gravity medium conditions. J. Biotechnol., 110, 287-293.
2. Bergogne-Berezin, E. (2000) Treatment and prevention of antibiotic associated diarrhea. Int. J. Antimicrob. Agents, 16, 521-526.
3. Bjorkqvist, S., Ansell, R., Adler, L., and Liden, G. (1997) Physiological response to anaerobicity of glycerol-3-phosphate dehydrogenase mutants of Saccharomyces cerevisiae. Appl. Environ. Microbiol., 63, 128-132.
4. Bléhaut, H., Massot, J., Elmer, G. W., and Levy, R. H. (1989) Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm. Drug Dispos., 10, 353-364.
5. Boddy, A. V., Elmer, G. W., McFarland, L. V., and Levy, R. H. (1991) Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharm. Res., 8, 796-800.
6. Buts, J. P., Corthier, G., and Delmee, M. (1993) Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J. Pediatr. Gastroenterol. Nutr., 16, 419-425.
7. Castagliuolo, I., LaMont, J. T., Nikulasson, S. T., and Pothoulakis, C. (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect. Immun., 64, 5225-5232.
8. Edwards-Ingram, L., Gitsham, P., Burton, N., Warhurst, G., Clarke, I., Hoyle, D., Oliver, S. G., and Stateva, L. (2007) Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl. Environ. Microbiol., 73, 2458-2467.
9. Elmer, G. W. and Corthier, G. (1991) Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can. J. Microbiol., 37, 315-317.
10. Elmer, G. W., McFarland, L. V., Surawicz, C. M., Danko, L., and Greenberg, R. N. (1999) Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol. Ther., 13, 1663-1668.
11. Fietto, J. L., Araujo, R. S., Valadao, F. N., Fietto, L. G., Brandao, R. L., Neves, M. J., Gomes, F. C., Nicoli, J. R., and Castro, I. M. (2004) Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can. J. Microbiol., 50, 615-621.
12. Graff, S., Chaumeil, J. C., Boy, P., Lai-Kuen, R., and Charrueau, C. (2008) Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition. Biol. Pharm. Bull., 31, 266-272.
13. Guslandi, M., Giollo, P., and Testoni, P. A. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol., 15, 697-698.
14. Guslandi, M., Mezzi, G., Sorghi, M., and Testoni, P. A. (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci., 45, 1462-1464.
15. Ludovico, P., Sousa, M. J., Silva, M. T., Leao, C., and Corte-Real, M. (2001) Saccharomyces cerevisiae commits to a programmed cell death process in response to acetic acid. Microbiology, 147, 2409-2415.
16. McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K. E., and Cox, J. L. (1995) Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am. J. Gastroenterol., 90, 439-448.
17. McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Fekety, R., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K. E., Coy, J. L., Noorani, Z. and et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA, 271, 1913-1918.
18. Osorio, H., Silles, E., Maia, R., Peleteiro, B., Moradas-Ferreira, P., Gunther Sillero, M. A., and Sillero, A. (2005) Influence of chronological aging on the survival and nucleotide content of Saccharomyces cerevisiae cells grown in different conditions: Occurrence of a high concentration of UDP-N-acetylglucosamine in stationary cells grown in 2% glucose. FEMS Yeast Res., 5, 387-398.
19. Posteraro, B., Sanguinetti, M., Romano, L., Torelli, R., Novarese, L., and Fadda, G. (2005) Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae. Int. J. Food Microbiol., 103, 295-304.
20. Pothoulakis, C., Kelly, C. P., Joshi, M. A., Gao, N., O'Keane, C. J., Castagliuolo, I., and Lamont, J. T. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology, 104, 1108-1115.
21. Surawicz, C. M., Elmer, G. W., Speelman, p., McFarland, L. V., Chinn, J., and van Belle, G. (1989) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology, 96, 981-988.
22. Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Felkety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., and Elmer, G. W. (2000) The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis., 31, 1012-1017.
23. Thomsson, E., Gustafsson, L., and Larsson, C. (2005) Starvation response of Saccharomyces cerevisiae grown in anaerobic nitrogen- or carbon-limited chemostat cultures. Appl. Environ. Microbiol., 71, 3007-3013.